The purpose of a Phase 1 trial is not to cure anyone. That's not what it's designed to do. The purpose is to establish whether a compound is safe to give to humans, at what doses, and what side effects emerge. Efficacy — whether it actually works — is a question for Phase 2 and 3. Phase 1 is about safety and dose-finding.
Understanding this changes how you think about the risk-benefit calculation.
Two very different populations
Phase 1 trials recruit two completely different types of participants, and the experience and risk profile are almost nothing alike.
Healthy volunteers are recruited for most non-oncology Phase 1 trials — testing new drugs for conditions like hypertension, diabetes, or inflammatory diseases. You don't have the condition the drug is designed to treat. You're participating to help researchers understand how the drug behaves in a healthy human system. The drugs used in these trials have passed extensive preclinical testing; the main unknowns are how humans metabolize them and what the side effect profile looks like. Serious adverse events in healthy volunteer Phase 1 trials are uncommon but not impossible.
Patients with the target disease are the primary participants in oncology Phase 1 trials, where healthy volunteers aren't appropriate. These are often people whose cancer has progressed through standard treatment options. The risk calculation here is genuinely different: the potential benefit is also higher, and the alternative — continuing with treatments that have stopped working — carries its own significant risks.
What dose escalation means for you
Phase 1 trials typically use a dose escalation design: the first participants receive a low dose, safety is assessed, then the dose is increased for the next group. If you enroll early, you may receive a sub-therapeutic dose — not enough to produce a meaningful treatment effect, but also the lowest-risk position. If you enroll later in the escalation sequence, you're receiving higher doses where more efficacy data may be available, but the side effect profile is also more established.
Ask the study team where you'd be entering the dose escalation sequence. It's a reasonable question, and it matters for your risk assessment.
The preclinical requirement
A drug doesn't arrive in Phase 1 from nowhere. Before any Phase 1 trial is approved, the sponsor must present substantial preclinical data — typically years of animal studies showing what the compound does, at what doses it becomes toxic, and what its pharmacological profile looks like. The FDA and equivalent authorities review this before approving the IND (Investigational New Drug application) that allows human testing.
This doesn't eliminate risk. Animal models don't perfectly predict human responses. But it does mean that Phase 1 is not a first guess. It's a carefully structured next step in a long development process.
The monitoring intensity
Phase 1 trials are the most intensively monitored of any trial phase. Participants are typically observed for hours after each dose. Vital signs are checked repeatedly. Blood is drawn at multiple time points to track how the drug moves through the body. For inpatient Phase 1 studies, participants may stay overnight or for multiple days. The monitoring density is both a protection and a significant time commitment.
How to decide
For healthy volunteers: the main questions are whether the compensation justifies the time and minor risk, and whether the study team is professional and transparent about what they know and don't know. A team that can't answer specific questions about the compound's preclinical safety profile is a yellow flag.
For patients: the decision is more complex and should involve your treating physician. The key question is whether participation means stopping or pausing treatment that's currently working. If standard options have been exhausted and the Phase 1 compound shows a plausible mechanism of action for your specific case, the calculation may favor participation. That calculation is yours and your doctor's to make together, not mine to make for you.